Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ori-C101 in Advanced HCC
NCT05652920Phase 2Recruiting
- Sponsor
- OriCell Therapeutics
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of ORI-C101 in hepatocellular carcinoma (HCC), sponsored by OriCell Therapeutics. Started Dec 2022; status: recruiting.
02
Drugs
ORI-C101
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05652920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652920.